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Abstract 23 
Complement activation leads to membrane-attack complex (MAC) formation which can lyse 24 
not only pathogens but also host cells. Histones can be released from the lysed or damaged 25 
cells and serve as a major type of damage-associate molecular pattern (DAMP), but their 26 
effects on the complement system are not clear. In this study, we pulled down two major 27 
proteins from human serum using histone-conjugated beads, one was C-reactive protein and 28 
the other was complement component C4 as identified by mass spectrometry.  In Surface 29 
Plasmon Resonance (SPR) analysis, histone H3 and H4 showed stronger binding to C4 than 30 
other histones with Kd around 1.0 nM. The interaction did not affect C4 cleavage to C4a and 31 
C4b. Since histones bind to C4b, a component of C3 and C5 convertases, their activities were 32 
significantly inhibited in the presence of histones. Although it is not clear whether the 33 
inhibition was achieved through blocking C3 and C5 convertase assembly or just through 34 
reducing their activity, the outcome was that both classical and mannan-binding lectin (MBL) 35 
pathways were dramatically inhibited.  Using a high concentration of C4 protein, histone-36 
suppressed complement activity could not be fully restored, indicating C4 is not the only 37 
target of histones in those pathways.  In contrast, the alternative pathway was almost spared 38 
but the overall complement activity activated by zymosan was inhibited by histones. 39 
Therefore, we b lieve that histones inhibiting complement activation is a natural feedback 40 
mechanism to prevent the excessive injury of host cells.   41 
 42 
 43 
 44 
 45 
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Introduction The Complement system forms a major part of the host response to infection 46 
and cellular injury(1, 2). This system is intricately involved in these processes and  consists 47 
of a cascade of more than 50 proteins, participating in three activation pathways; namely the 48 
classical, mannose binding lectin (MBL) and alternative pathways(2). The classical pathway 49 
recognises antigen-antibody complexes contained on the surface of pathogenic factors, 50 
including gram-negative bacteria, viruses and damaged cells(3). The MBL pathway binds 51 
mannose containing pathogenic surfaces(4). Finally, the alternative pathway directly targets 52 
surface carbohydrate regions on pathogens such as viruses, bacteria and fungi(5). The 53 
terminal pathway of complement activation by different stimuli is the formation of C3 and C5 54 
convertases to lead to assembly of C5b-9 complex, the membrane- attack complex (MAC) to 55 
lyse pathogens. Many products generated during complement activation are also able to 56 
opsonize damaged cells or pathogens to facilitate phagocytosis(1, 2). In this way, 57 
complement activation enhances the ability of antibodies and phagocytic cells to clear 58 
invading pathogens and cellular debris from the circulation(6). 59 
 60 
Complement activation not only kills pathogens but also damages host cells during an 61 
inflammatory reaction and excessive activation contributes to inflammation-driven tissue 62 
injury(7).  Host cell lysis will release cell breakdown products, including DNA and histones, 63 
and those damage-associate molecular patterns (DAMPs) have been demonstrated to play 64 
important roles in disease progression and host immune responses(8-10). Histones, the most 65 
abundant and important DAMPs, can be detected in blood taken from many critical illnesses, 66 
such as severe trauma(11), severe sepsis(12, 13) and necrotising pancreatitis(14). Histones 67 
are positively charged proteins and have high affinity for negatively charged phospho-groups 68 
in DNA or cell membranes. Histone binding to cell membrane allows ions, particularly Ca
2+
 69 
influx into cells to cause harmful effects to cells contacted(11). In addition, histones are also 70 
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the ligands of Toll-like receptors (TLR)-2, 4 and 9 receptors to trigger immune response, 71 
including inflammasome activation and cytokine release(15-17). Histones also interact with 72 
coagulation factors in the circulation to promote thrombin generation, fibrin deposition and 73 
systemic coagulation activation(18-22). In animal models, extracellular histones have been 74 
shown to mediate multiple organ injury and even death in sepsis(13, 23).  Clinically, 75 
correlation between circulating histone levels and organ injury as well as disease severity has 76 
also been demonstrated(12).  77 
 78 
Recently, we found that extracellular histones interact with complement component 4 (C4) 79 
protein. Complement C4 coded by both C4A and C4B genes is synthesised into a single 80 
peptide (precursor) and then cleaved into α (98kDa), β (73kDa) and γ (33kDa) chains(24, 25).  81 
Upon complement activation, C4 is cleaved by C1S enzyme into C4a (kDa) and C4b, the 82 
latter mainly participates in classical and lectin pathways  by forming C3 and C5 convertases, 83 
whist C4a as an anaphylatoxin enhances smooth muscle contraction, histamine release and 84 
vascular permeability as well as serving as a chemotaxis and inflammatory mediator(26, 27). 85 
In many disease conditions, particular in sepsis, complement activation(28) and histone 86 
release(12) coexist. The outcome of histones binding to C4 appears important and this study 87 
is trying to understand the pathophysiology related to the complement system and 88 
extracellular histones. 89 
 90 
Materials and Methods 91 
Human plasma and serum 92 
Citrate plasma and serum were isolated from whole blood drawn from critically ill patients, 93 
according to the protocol granted by Liverpool Adult Ethical Committee (Ref: 13/NW/0089).  94 
Human normal serum was purchased from CompTech, USA.  95 
Fo
r P
ee
r R
ev
iew
. D
o n
ot 
dis
trib
ute
. D
es
tro
y a
fte
r
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
us
e.
5 
 
Fractionation of human serum and plasma by ultracentrifugation 96 
Citrate plasma and serum (1 ml) from patients were fractionated by ultracentrifugation at 97 
40,000 rpm (4ºC) for one hour and then 6 layers of equal volume fractions (166 ul per 98 
fraction) were collected. Histones and Histone-DNA complexes were then measured in each 99 
fraction by Western blotting and ELISA (Cell death detection ELISA PLUS, Roche), 100 
respectively, as previously described.(11) 101 
Isolation of histone binding protein from plasma and mass spectrometry analysis 102 
Isolated citrated plasma was diluted with 2 × phosphate buffered saline (PBS) (v/v) and 103 
centrifuged to eliminate insoluble contents.   The harvested supernatant was then pre-cleared 104 
using blank Sepharose resin and then loaded on a CNBr-activated Sepharose 4B (GE 105 
Healthcare, Little Chalfont, UK) column conjugated with calf thymus histones (Roche, West 106 
Sussex, UK). After a high stringency wash with PBS+0.5% (v/v) Tween-20 (Sigma-Aldrich, 107 
Dorset, UK) followed by PBS, histone-binding proteins were eluted and separated by gel 108 
electrophoresis.  Gel slices from SDS-PAGE were washed (2 x 30 min) with 50% 109 
acetonitrile, 0.2M ammonium bicarbonate pH 8.9 and then dried in a rotary evaporator. The 110 
slices were re-swollen in RHB [2 M urea, 0.2 M ammonium bicarbonate pH 7.8] containing 111 
0.2 μg trypsin and incubated at 37ºC overnight. Excess RHB was then removed and peptides 112 
were extracted from the gel slices with 60% acetonitrile, 0.1% TFA. The total peptide extract 113 
was concentrated in a rotary evaporator and then desalted using C18 ZipTips according to the 114 
manufacturer’s instructions. MS analysis was performed using a MALDI-Tof instrument 115 
(Waters-Micromass) using a saturated solution of alpha-cyano-4 hydroxycinnaminic acid in 116 
50% acetonitrile/0.1% trifluoroacetic acid.  117 
 118 
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Detection of Histone-C4 complexes by ELISA 119 
Histone-C4 complexes were detected in normal and critically ill patient plasma using Cell 120 
death detection ELISA PLUS kit (Roche) with modification. In brief, normal plasma was pre-121 
incubated with different concentrations of calf thymus histones for 10 minutes. Histones in 122 
plasma were first captured by biotinylated-anti-histone antibody immobilized on streptavidin-123 
coated 96 well plates. After extensive washing, rabbit anti-human C4 antibody (Abcam) 124 
followed by anti-rabbit-HPR antibody were used to probe histone-C4 complexes. Arbitrary 125 
units (AU) were calculated based on the absorbance (450nm) to represent the relative levels 126 
of the complexes.  127 
Western blotting using HRP conjugated C4 128 
In order to double confirm the interaction of C4 with individual histones by different assay, 2 129 
µg of H2A, H2B, H3 and H4, 4 µg of H1 and 6 µg of S100P (as control) were subjected to 130 
Western blotting with HRP-conjugated C4 protein. C4 was purchased from Fitzgerald, USA 131 
and conjugated using Lighting-Link HRP conjugation kit (Innova bioscience, Babraham, 132 
Cambridge, UK, ref. 701-0000) according to the procedure recommended by the 133 
manufacturer.  134 
Surface Plasmon resonance measurements 135 
The binding parameters of C4 to individual histones, including the equilibrium dissociation 136 
constant (Kd), affinities on-rates (kon), and off-rates (koff) were measured by surface plasmon 137 
resonance analysis on a Proteon XPR36 system (Bio-Rad). Chips coated with 20µg.ml 138 
streptavidin (GLH, GE Healthcare), which could directly interact with histones,(29)  were 139 
used for immobilizing individual histones and measuring binding affinities to C4. Running 140 
buffer (10 mM HEPES pH7.4, 150 mM NaCl (0.05% Tween 20) and regeneration buffer (0.1 141 
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M glycine pH2.2) were used throughout the assay. Five µg/mL of each recombinant histone 142 
(H1, H2A, H2B, H3 or H4) in running buffer was captured only on the surface of flow cells 143 
Fc (2-6) with Fc1 set as blank. For kinetics, a concentration series C4 was injected at a flow 144 
rate of 10 µl/min over both captured histone surface and reference surface (blank) at 20
o
C. 145 
Kds were calculated using software provided by the manufacturer.  146 
Complement activity assay 147 
The effect of histones on complement activity in the three pathways was measured using   148 
COMPL300 Total Complement Functional Screen kit from Wielisab (Sweden). Briefly, 149 
mixtures of the reaction were added to strips of wells for classical pathway (CP) estimation, 150 
that were precoated with IgM, strips for alternative pathway (AP) determination were coated 151 
with LPS, while Mannan binding lectin pathway (MBL) strips were coated with mannan. 152 
Normal human sera were diluted 1/101 (CP and MBL) and 1/18 (AP) assay in specific kit 153 
buffers, to ensure that only the pathway in question was activated.(30) After one hour of 154 
incubation at 37 °C then washing the strips, alkaline phosphatase-conjugated antihuman C5b-155 
9 was added before incubation at room temperature for 30 min. Additional washing was 156 
performed, the substrate was added, and the wells were incubated for 30 min. Finally, 157 
absorbance values were read at 405 nm. In each assay, standard positive and negative control 158 
sera provided in the kit were used. The complement activity for each pathway was expressed 159 
as a percentage of the activity of the calibrating serum. C3a and C5a were measured using 160 
C3a and C5a ELISA kits (e-Bioscience). C5b-9 induced by zymosan (Comp Tech) was 161 
measured using an ELISA kit from Quidel Corporation, USA. 162 
Antibody and heparin blocking assay 163 
Anti-histone reagent, non-anticoagulant heparin 20µg/ml, was incubated with 20μg/ml H1, 164 
H2A, H2B, H3 or H4 proteins, or 20 μg/ml anti-histone H4 antibody incubated with H4, prior 165 
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to complement activation using Wieslab COMPL CP310 kit.  Percentage changes were 166 
calculated by comparing to untreated (100%).  167 
C4 cleavage assay 168 
C1S (50µg/ml, Comp Tech, USA) was incubated with C4 (250µg/ml) in the presence or 169 
absence of histones (100µg/ml) at 37
◦
C for 30 mins, then 2X SDS loading buffer was added  170 
and  boiled for 10 mins prior to SDS-PAGE. The gel was stained with Coomassie brilliant 171 
blue or subjected to Western blotting with anti-C4a antibody (Comp Tech). The C4a band 172 
intensities were measured using software 7.05 GeneSnap from Syngene and fold changes 173 
were calculated. 174 
Cell viability assay 175 
Viability was assessed using a WST-8 cell proliferation assay kit (Enzo Life Sciences), as 176 
described previously(31). Briefly, 5x10
4
 cells were seeded into each well of a 96-well plate 177 
and grown until fully confluent (24 hours). Cells were treated with histones at 100 µg/ml with 178 
and without different concentrations of C4 (10-300 µg/ml) for 1 hour. After treatment, the 179 
medium was changed to a fresh 100 μl growth media and 10 µl of WST-8 dye was added to 180 
each well, followed by further incubation for 2 hrs. Viability was assessed by measuring the 181 
absorbance at 450 nm against a reference 650 nm using a microplate reader (Multiskan 182 
Spectrum, Thermoelectron Corporation). Viability of untreated cells was set as 100% for 183 
comparison. 184 
Statistical analysis 185 
Intergroup differences were analysed using ANOVA followed by Student-Newman-Keuls test. Two 186 
group comparisons with or without treatment used Student’s t test unless otherwise specified. 187 
Results 188 
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Free histones exist in circulation and can form complexes with complement C4 189 
Although it is known that nucleosomes can be released after cell death or NETs 190 
formation(32-36), it is not clear whether circulating histones are still exclusively in the form 191 
of histone-DNA complexes. Using ultracentrifugation to fractionate plasma or serum with 192 
high circulating histone levels into 6 fractions, we found that histones were detectable in all 6 193 
fractions (Figure 1A upper panel). However, DNA-histone complexes (most likely 194 
nucleosomes) were in fraction 6 only (bottom fraction) (Figure 1A, lower panel). No 195 
difference was found between plasma and serum. This experiment demonstrated that DNA 196 
free-histones exist in circulation. 197 
Histone-conjugated Sepharose beads were then used to pull down human plasma proteins. 198 
Following extensive washing, proteins bound to histone-beads were eluted. Multiple proteins 199 
were visualised on Coomassie blue stained gels with two major protein bands at 200 
approximately 70 kDa and 25 kDa (Figure 1B). Following liquid chromatography-mass 201 
spectrometry (LC-MS/MS) analysis, complement C4 and C-reactive protein (CRP) were 202 
identified (Figure 1C and 1D). CRP has been reported to be a major histone-binding protein 203 
that neutralises histone toxicities(37). As to complement C4, we could detect histone-C4 204 
complexes in normal plasma spiked with calf thymus histones (Figure 1E) and also in plasma 205 
from critically ill patients with high circulating histone levels (Figure 1F), confirming that  206 
histones form complexes with C4 in vivo. In this study, we further investigated the 207 
interaction of histones with C4 and its potential biological roles and significance. 208 
Individual histones bind to complement C4 with different affinity 209 
To determine the relative binding extents of individual histones to C4, equal molar 210 
concentrations of individual histones were subjected to gel overlay assay (Figure 2A upper) 211 
with Coomassie blue stained gel demonstrated equal loading (Figure 2A lower). Figure 2A 212 
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shows that H3 and H4 predominantly bound to C4 and to a lesser extent H1 and H2B, with 213 
H2A-C4 binding undetectable using this method. To determine the comparative binding 214 
strengths under physiological conditions, we used surface plasmon resonance (SPR, Biocore 215 
X-100) (Figure 2B-F). Table 1 shows that H3 (KD = 0.760.12 nM) and H4 (KD = 0.910.07 216 
nM) had much higher binding affinity than equal molar concentrations of H1 (KD = 217 
7.260.80 nM) and H2B (KD = 9.451.43 nM), with weak binding to H2A (KD = 12.670.59 218 
nM). 219 
Histones dramatically inhibit classical and lectin but not alternative pathways 220 
To investigate functional consequence, we used a Complement functional screen kit to 221 
measure the effects of histones on the activation of classical, MBL and alternative pathways.  222 
Pre-incubation of different concentrations of calf thymus histones with human serum 223 
significantly reduced the production of MAC by activated classical and MBL pathways. 224 
Significant reduction could be detected at 10 μg/ml histones, and only trace amount of MAC 225 
could be formed in the presence of 50 μg/ml histones (Figure 3A).  In contrast, histones 226 
showed much less effect on the alternative pathway and 50 μg/ml histones only reduced 227 
MAC about 20%. To evaluate the overall effect of histones on complement activation in 228 
human serum, zymosan was used to activate complement in the presence or absence of 229 
histones. We found that histones at 50 μg/ml could significant inhibit the production of MAC 230 
induced by zymosan (Figure 3B).  We also assessed the role of individual histones in the 231 
classical (C, D), and MBL (E, F) pathway activation and found that 20 g/ml individual 232 
histones started to significantly reduce activation of both classical and MBL pathways, with 233 
H4 and H2B showing the most significant effects.   234 
Anti-histone reagents can rescue complement activation 235 
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To demonstrate the specificity of histones on complement activation, anti-histone H4 and 236 
non-anticoagulant heparin that have been shown to specifically inhibit histone toxicity both in 237 
vitro and in vivo(11, 38), were used. Heparin could reverse the inhibition of both classical and 238 
MBL pathways by all individual histones (Figure 4A, B), whist anti-histone H4 could 239 
significantly rescue the H4-inhibited complement activation of both pathways (Figure 4C, D). 240 
Those data demonstrated that the effect of histones on complement inactivation was specific 241 
to histones. 242 
Histones do not affect C4 cleavage but significantly reduce C3 and C5 convertase 243 
activity  244 
To clarify the molecular mechanism of histone-inhibited complement activation through 245 
interaction with C4, the effect of histones on the cleavage of C4 to C4b and C4a by C1s, a 246 
process of C4 activation, was investigated. We found that histones showed no effect on the 247 
production of C4a (Figure 6 A-B), indicating histone binding does not affect the ability of 248 
C1s to cleave C4 protein. Further investigation showed that histones bind to C4b but not C4a 249 
(Figure 6C). However, in the presence of histones, the production of C3a and C5a were 250 
significantly reduced in the classical and MBL pathways but not the alternative pathway 251 
(Figure 6E-F), suggesting that histone-bound C4b is not as efficient as C4b alone in forming 252 
active C3 and C5 convertases. The overall C3a, C5a and C5b-9 production induced by 253 
zymosan (Figure 6E-F) was significantly reduced by histones due to the suppression of both 254 
classical and MBL pathways. 255 
Excess C4 protein only partially rescues histone-inhibited complement activation but 256 
significantly reduces cytotoxicity of histones 257 
Using C4 protein up to 300 μg/ml, only 1/3 of the maximal complement activity of classical 258 
and MBL pathways could be recovered in the presence of calf thymus histones up to 20 259 
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μg/ml (Figure 5A, B). However, the zymosan-induced complement activation could be 260 
recovered by 300 μg/ml C4 from 25% to 70% of total activity in the presence of 20 μg/ml 261 
histone H4 protein (Figure 5C). This observation suggests that histones may also target other 262 
components of the complement system rather than C4 alone. On the other hand, C4 protein 263 
could significantly reduce the cytotoxicity of histones to cultured endothelial cells (Figure 264 
5D).  265 
Discussion 266 
Complement activation generates membrane attack complexes (MAC) to lyse cells and leads 267 
to cell death and content release, including histones. The inhibitory effects of histones on 268 
complement activation could form a physiological feedback loop to prevent over production 269 
of MAC and excessive tissue damage. This finding is novel and with evidence that histone-270 
C4 complexes exist in the circulation of critically ill patients, adds relevance to filling the 271 
unknown gap on communication between targeted cells and complement (Figure 7).  272 
Complement C4 is activated by C1s cleavage to produce C4a and C4b. The C4b is the 273 
essential component of both C3 and C5 convertase, a common step of both classical and 274 
MBL pathways (Figure 7).  Histones strongly bind to C4 but do not affect C4 activation 275 
because there is no difference in C4a production in the presence or absence of histones. 276 
Histones binds to C4b but not C4a, therefore their major effect is to reduce the activity of C3 277 
and C5 convertase, as indicated by reduction of C3a and C5a, the products of C3 and C5 278 
activation.  One mechanism could be the interruption of the convertase formation and the 279 
other could just affect the catalytic activity even though the complexes are formed.  Since the 280 
life time of C3 and C5 convertases in solution are very short, it is difficult to distinguish the 281 
two potential mechanisms. In contrast, histones have minimal effect on alternative pathways, 282 
in which C4b is not required.  However, the overall effect is the significant reduction of C3 283 
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and C5 activation as well as the MAC formation. This finding suggests that C4 is a major 284 
target of the complement system. However, excess of C4 could not fully restore the 285 
complement activation in the presence of histones. This finding suggests that histones may 286 
have more targets on those pathways, such as C1 or C2 (Figure 7). This needs further 287 
investigation.  288 
It is known that circulating C4 is about 0.4 mg/ml, but no histones could be detected in blood 289 
from heathy donors(39). In critical illness, for example sepsis, histones could surge up to 290 
100-200 mg/ml(12) but C4 was reported to decrease due to consumption(39). Therefore the 291 
high levels of histones are sufficient to inhibit both classical and MBL pathways. Although 292 
high levels of C4 could efficiently detoxify histones in vitro, the low levels of C4 in sepsis 293 
may not be sufficient to neutralise high levels of histones. In non-critical illness, such as 294 
chronic inflammatory diseases with complement activation, the circulating histones could be 295 
very low but the local concentration of histones released from lysed cells may be high and 296 
sufficient to suppress further complement activation and prevent excessive injury of host 297 
tissues.   However, further laboratory experiments and clinical investigation are required to 298 
clarify those points.  299 
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Figure legends 422 
Figure 1.  Identification of Complement component 4 as a histone binding protein. (A) 423 
Critically ill patient plasma was separated into 6 fractions (1 = upper fraction; 6 = lower 424 
fraction) based on density using ultracentrifugation. Circulating histones (top panel) were 425 
measured by Western blot and histone-DNA complexes (bottom panel) quantified by ELISA 426 
(n=4). (B) Using histone-conjugated Sepharose, a few proteins were pulled down. Among 427 
them, there were 2 major bands on Coomassie blue stained gel, one was complement C4 and 428 
the other was CRP, as identified by mass spectrometry. (C) and (D) The typical spectra of 429 
the two major proteins are presented. (E) Histone-C4 complexes were detected by ELISA 430 
following the addition of different concentrations of histones to normal plasma. (F) Histone-431 
C4 complexes are elevated in critically ill patient plasma compared to normal (n=3). 432 
Figure 2. Complement C4 binds to individual histones. (A) Two μg individual histones 433 
and 6 μg S100P as a control were subjected to SDS-PAGE. One gel was transferred onto 434 
PVDF membrane and probed with HRP-conjugated C4 protein (upper panel). The other gel 435 
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was stained with Coomassie brilliant blue (lower panel). (B-F) SPR analysis. Individual 436 
histones were first immobilized on streptavidin surfaces.  Different concentrations of C4 were 437 
applied onto each surface and typical binding curves are presented.   438 
Figure 3.  Histones inhibit complement activation. (A) Classical, MBL and alternative 439 
complement pathways were activated by IgM, mannan and LPS respectively in the absence 440 
or presence of different concentrations of calf thymus histones (0-50 µg/ml). MAC was 441 
detected by anti-human C5b-9 antibodies. The complement activity of control wells without 442 
histones was set up as 100%. The Means±SD of relative activities were presented. (B) Shows 443 
the Means±SD of relative activities activated by zymosan (activating different pathways) in 444 
the presence of different concentration of calf thymus histones (0-50 µg/ml). The Means±SD 445 
of relative activities of Classical (C) and MBL (D) pathways in the presence of 20µg/ml  446 
individual histones. The Means±SD of relative activities of Classical (E) and MBL (F) 447 
pathways in the presence of different concentration of individual histones (0-50 µg/ml).  448 
Means±SD were calculated from at least 3 independent experiments. ANOVA test, *p<0.05 449 
compared to untreated.   450 
Figure 4.  Anti-histone treatment rescues complement activation. (A) and (B) non-451 
anticoagulant heparin (20 µg/ml) was used to rescue complement activities of classical (A) 452 
and MBL pathways inhibited by individual histones (20 µg/ml). (C) and (D) Anti-histone H4 453 
antibody (12 µg/ml) was used to rescue complement activities of Classical (C) and MBL (D) 454 
inhibited by H4 (20 µg/ml).   The Means±SD of relative activities from at least 3 independent 455 
experiments were presented. ANOVA test, *P<0.05 when compared to untreated. #P<0.05 456 
when compared to that treated with histone alone.  457 
Figure 5. Histones show no effect on C4 cleavage but significantly reduce C3 and C5 458 
convertase activities. (A) In vitro cleavage of C4 by C1S in the presence or absence of 459 
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histones. C4 (250 µg/ml) was incubated with C1S (50 µg/ml, active enzyme to cleave C4 into 460 
C4a and C4b) ± calf thymus histones (100 µg/ml) at 37
◦
C for 30 mins and subjected to 8-18% 461 
gradient SDS-PAGE along with calf thymus histones, C4a, C4b, C4 and C1s proteins. A 462 
typical Coomassie brilliant blue stained gel is presented. (B) A typical Western blot with anti-463 
C4a antibody is presented (Upper panel). Fold changes were calculated by setting up C4a 464 
intensity without histones as 1.0. The relative fold changes of that with calf thymus histones 465 
from 3 independent experiments are presented (Lower panel). Student’s t test, P=0.2.  (C) 466 
Two μg C4, C4b, C4a and S100P (as a control) were subjected to blotting with HRP-467 
conjugated calf thymus histones. A typical blot is presented. (D-F) Complement in serum 468 
was activated by IgM (Classical pathway, CP), Mannan (MBL), LPS (Alternative pathway, 469 
AP) or zymosan in the absence or presence of calf thymus histones treated (50 µg/ml) for 1hr 470 
at 37
◦
C. Then the C3a (D), C5a (E) or MAC levels (F) were detected by ELISA. Means±SD 471 
from at least 3 independent experiments are presented. ANOVA test, *P<0.05 when 472 
compared to that without histones.  473 
Figure 6. Effect of C4 protein on histones. (A-B) C4 protein affects histone-inhibited 474 
complement activity. Adding C4 protein (0-300 µg/ml) rescued 20 μg/ml histone H4-475 
inhibited activation of Classical pathway (A), MBL pathway (B). (C) zymosan activated 476 
complement activity in the absence or presence of histone H4 20 μg/ml and C4 protein 300 477 
μg/ml (histone H4: C4 molar ratio= 1:1). (D) Human endothelial cell line, EA.hy926, was 478 
treated with 100 μg/ml calf thymus histones in the presence 0-300 μg C4 proteins for one 479 
hour. The percentage of cell viability was detected using WST8 cell viability kit. Means±SD 480 
from 3 independent experiments are presented. ANOVA test, *P<0.05 when compared to 481 
histone alone. 482 
Figure 7. Schematic representation of the effect of histones in the complement pathway. 483 
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